Sign inCreate account

Report workspace

Add to folder
NCT00306189COMPLETEDanonymous

Dose Response Study of AMG 162 (Denosumab) in Subjects With Osteoporosis - A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects -

Sponsor

Source record

Amgen

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo

Indication / condition

AI-normalized

Osteoporosis

Intervention

Source record

100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo

Related intelligence directories

Indication directory: OsteoporosisModality directory: monoclonal antibodyTarget directory: 100 mg AMG 162

Source & freshness

Source record

NCT ID

NCT00306189

Original source

ClinicalTrials.gov

Source last updated

Jun 20, 2013

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00306189

Title

Dose Response Study of AMG 162 (Denosumab) in Subjects With Osteoporosis - A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects -

Sponsor

Amgen

Status

COMPLETED

Phase

PHASE2

Condition raw

Osteoporosis

Condition normalized

Osteoporosis

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo

Target normalized

100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo

Interventions

100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo

Public preview

Source record

The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in Japanese postmenopausal osteoporotic subjects compared with those treated with placebo over 12 months.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Dose Response Study of AMG 162 (Denosumab) in Subjects With Osteoporosis - A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects -

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT00306189

Status

COMPLETED

Phase

PHASE2

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in Japanese postmenopausal osteoporotic subjects compared with those treated with placebo over 12 months.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 20, 2013
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00306189

Indication

Osteoporosis

Modality

monoclonal antibody

Target

100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo

Intervention

100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.